Oloya, Jamaica P.

HRN: 21-96-64  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/20/2022
CO-AMOXICLAV 625MG (TAB)
10/20/2022
10/28/2022
PO
625mg
Bid
G1P1 (1001) PU Del Via Nsvd With RMLE, RAT Confirmed, COVID 19 Mild
Waiting Final Action 

Indication:  Prophylaxis    Type of Infection:  URTISkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: